{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:25:44Z","timestamp":1793683544289,"version":"4.5.1"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"17","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cellular diversity, which is a hallmark of malignancy, can be generated by both genetic and nongenetic mechanisms. We describe here variability in the adhesive and migratory behavior of malignant plasma cell populations, including multiple myeloma\u2013derived lines and primary patient samples. Examination of the plasma cell lines ARH-77, CAG, and AKR revealed two distinct subpopulations of cells, one displaying highly adhesive properties (type A) and the other consisting of poorly adhesive, floating cells (type F). In the ARH-77 cell line, type A cells attach better to fibronectin and to human bone fragments and form paxillin-rich focal adhesions, whereas type F cells are highly motile and exert integrin-dependent bone marrow homing capacity in nonobese diabetic\/severe combined immunodeficient mice. Flow cytometry indicated that type A cells express significantly higher levels of CD45 and CD56 and lower levels of CD138 compared with type F cells. Interestingly, culturing of either type A or type F cells under nonselective conditions resulted in the development of mixed cell population similar to the parental ARH-77 cells. Analysis of bone marrow aspirates of multiple myeloma patients revealed that spicules within the aspirates are enriched with type A\u2013like cells. Nonadherent cells within the aspirate fluids express a marker profile similar to type F cells. This study indicates that multiple myeloma patients contain heterogeneous populations of malignant plasma cells that display distinct properties. Diverse subpopulations of malignant plasma cells may play distinct roles in the different biological and clinical manifestations of plasma cell dyscrasias, including bone dissemination and selective adhesion to bone marrow compartments. (Cancer Res 2006; 66(17): 8608-16)<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-1301","type":"journal-article","created":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T22:49:59Z","timestamp":1157150999000},"page":"8608-8616","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Generation and Regulation of Functional Diversity of Malignant Plasma Cells"],"prefix":"10.1158","volume":"66","author":[{"given":"Liat","family":"Nadav","sequence":"first","affiliation":[{"name":"1The Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, Israel and"},{"name":"2The Hematology Institute and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Zion","family":"Katz","sequence":"additional","affiliation":[{"name":"2The Hematology Institute and"},{"name":"4Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Baron","sequence":"additional","affiliation":[{"name":"2The Hematology Institute and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Cohen","sequence":"additional","affiliation":[{"name":"3The Orthopedic Department, Tel Aviv Sourasky Medical Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Naparstek","sequence":"additional","affiliation":[{"name":"2The Hematology Institute and"},{"name":"4Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Geiger","sequence":"additional","affiliation":[{"name":"1The Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, Israel and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2006,9,1]]},"reference":[{"key":"2022061622130044700_B1","doi-asserted-by":"crossref","unstructured":"Ho PJ, Campbell LJ, Gibson J, Brown R, Joshua D. The biology and cytogenetics of multiple myeloma. Rev Clin Exp Hematol\u20082002; 6: 276\u2013300.","DOI":"10.1046\/j.1468-0734.2002.00081.x"},{"key":"2022061622130044700_B2","doi-asserted-by":"crossref","unstructured":"Segeren CM, Sonneveld P, van der Holt B, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood\u20082003; 101: 2144\u201351.","DOI":"10.1182\/blood-2002-03-0889"},{"key":"2022061622130044700_B3","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol\u20081997; 97: 46\u201355.","DOI":"10.1046\/j.1365-2141.1997.72653.x"},{"key":"2022061622130044700_B4","doi-asserted-by":"crossref","unstructured":"Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am\u20081992; 6: 297\u2013322.","DOI":"10.1016\/S0889-8588(18)30346-0"},{"key":"2022061622130044700_B5","doi-asserted-by":"crossref","unstructured":"Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia\u20082003; 17: 203\u201310.","DOI":"10.1038\/sj.leu.2402717"},{"key":"2022061622130044700_B6","doi-asserted-by":"crossref","unstructured":"Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol\u20082003; 170: 1136\u201340.","DOI":"10.4049\/jimmunol.170.3.1136"},{"key":"2022061622130044700_B7","doi-asserted-by":"crossref","unstructured":"Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am\u20081997; 11: 27\u201342.","DOI":"10.1016\/S0889-8588(05)70413-5"},{"key":"2022061622130044700_B8","unstructured":"Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F. \u03b1(v)\u03b2(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica\u20082002; 87: 836\u201345."},{"key":"2022061622130044700_B9","doi-asserted-by":"crossref","unstructured":"Crossin KL, Krushel LA. Cellular signaling by neural cell adhesion molecules of the immunoglobulin superfamily. Dev Dyn\u20082000; 218: 260\u201379.","DOI":"10.1002\/(SICI)1097-0177(200006)218:2<260::AID-DVDY3>3.0.CO;2-9"},{"key":"2022061622130044700_B10","unstructured":"Masellis-Smith A, Belch AR, Mant MJ, Pilarski LM. Adhesion of multiple myeloma peripheral blood B cells to bone marrow fibroblasts: a requirement for CD44 and \u03b14\u03b27. Cancer Res\u20081997; 57: 930\u20136."},{"key":"2022061622130044700_B11","doi-asserted-by":"crossref","unstructured":"Van Driel M, Gunthert U, van Kessel AC, et al. CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells. Leukemia\u20082002; 16: 135\u201343.","DOI":"10.1038\/sj.leu.2402336"},{"key":"2022061622130044700_B12","doi-asserted-by":"crossref","unstructured":"Vincent T, Jourdan M, Sy MS, Klein B, Mechti N. Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein. J Biol Chem\u20082001; 276: 14728\u201336.","DOI":"10.1074\/jbc.M003965200"},{"key":"2022061622130044700_B13","doi-asserted-by":"crossref","unstructured":"Turley EA, Belch AJ, Poppema S, Pilarski LM. Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant B lymphocytes. Blood\u20081993; 81: 446\u201353.","DOI":"10.1182\/blood.V81.2.446.446"},{"key":"2022061622130044700_B14","doi-asserted-by":"crossref","unstructured":"Pilarski LM, Masellis-Smith A, Belch AR, Yang B, Savani RC, Turley EA. RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes, and malignant B cells: a mediator in B cell malignancy? Leuk Lymphoma\u20081994; 14: 363\u201374.","DOI":"10.3109\/10428199409049691"},{"key":"2022061622130044700_B15","doi-asserted-by":"crossref","unstructured":"Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood\u20082003; 102: 4504\u201311.","DOI":"10.1182\/blood-2003-01-0016"},{"key":"2022061622130044700_B16","doi-asserted-by":"crossref","unstructured":"Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J, Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood\u20082003; 101: 1128\u201340.","DOI":"10.1182\/blood-2002-06-1737"},{"key":"2022061622130044700_B17","doi-asserted-by":"crossref","unstructured":"Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood\u20082003; 101: 4998\u20135006.","DOI":"10.1182\/blood-2002-11-3385"},{"key":"2022061622130044700_B18","doi-asserted-by":"crossref","unstructured":"Mattioli M, Agnelli L, Fabris S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene\u20082005; 24: 2461\u201373.","DOI":"10.1038\/sj.onc.1208447"},{"key":"2022061622130044700_B19","doi-asserted-by":"crossref","unstructured":"Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood\u20082004; 104: 607\u201318.","DOI":"10.1182\/blood-2004-01-0037"},{"key":"2022061622130044700_B20","unstructured":"Sharkey FE. Morphometric analysis of differentiation in human breast carcinoma. Tumor heterogeneity. Arch Pathol Lab Med\u20081983; 107: 411\u20134."},{"key":"2022061622130044700_B21","doi-asserted-by":"crossref","unstructured":"Pompeia C, Hodge DR, Plass C, et al. Microarray analysis of epigenetic silencing of gene expression in the KAS-6\/1 multiple myeloma cell line. Cancer Res\u20082004; 64: 3465\u201373.","DOI":"10.1158\/0008-5472.CAN-03-3970"},{"key":"2022061622130044700_B22","doi-asserted-by":"crossref","unstructured":"Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch. Science\u20082004; 305: 1622\u20135.","DOI":"10.1126\/science.1099390"},{"key":"2022061622130044700_B23","doi-asserted-by":"crossref","unstructured":"Gooding RP, Bybee A, Cooke F, et al. Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia. Br J Haematol\u20081999; 106: 669\u201381.","DOI":"10.1046\/j.1365-2141.1999.01602.x"},{"key":"2022061622130044700_B24","doi-asserted-by":"crossref","unstructured":"Choi SJ, Oba T, Callander NS, Jelinek DF, Roodman GD. AML-1A and AML-1B regulation of MIP-1\u03b1 expression in multiple myeloma. Blood\u20082003; 101: 3778\u201383.","DOI":"10.1182\/blood-2002-08-2641"},{"key":"2022061622130044700_B25","doi-asserted-by":"crossref","unstructured":"Treon SP, Teoh G, Urashima M, et al. Anti-estrogens induce apoptosis of multiple myeloma cells. Blood\u20081998; 92: 1749\u201357.","DOI":"10.1182\/blood.V92.5.1749.417k38_1749_1757"},{"key":"2022061622130044700_B26","doi-asserted-by":"crossref","unstructured":"Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-\u03baB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood\u20081999; 93: 3044\u201352.","DOI":"10.1182\/blood.V93.9.3044.409a13_3044_3052"},{"key":"2022061622130044700_B27","doi-asserted-by":"crossref","unstructured":"Akiyama SK, Yamada SS, Chen WT, Yamada KM. Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization. J Cell Biol\u20081989; 109: 863\u201375.","DOI":"10.1083\/jcb.109.2.863"},{"key":"2022061622130044700_B28","doi-asserted-by":"crossref","unstructured":"Mould AP, Garratt AN, Askari JA, Akiyama SK, Humphries MJ. Identification of a novel anti-integrin monoclonal antibody that recognises a ligand-induced binding site epitope on the \u03b21 subunit. FEBS Lett\u20081995; 363: 118\u201322.","DOI":"10.1016\/0014-5793(95)00301-O"},{"key":"2022061622130044700_B29","doi-asserted-by":"crossref","unstructured":"Kuwada SK, Li X. Integrin \u03b15\/\u03b21 mediates fibronectin-dependent epithelial cell proliferation through epidermal growth factor receptor activation. Mol Biol Cell\u20082000; 11: 2485\u201396.","DOI":"10.1091\/mbc.11.7.2485"},{"key":"2022061622130044700_B30","doi-asserted-by":"crossref","unstructured":"Zamir E, Katz BZ, Aota S, Yamada KM, Geiger B, Kam Z. Molecular diversity of cell-matrix adhesions. J Cell Sci\u20081999; 112: 1655\u201369.","DOI":"10.1242\/jcs.112.11.1655"},{"key":"2022061622130044700_B31","unstructured":"Wallace PK, Palmer LD, Perry-Lalley D, et al. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells. Cancer Res\u20081993; 53: 2358\u201367."},{"key":"2022061622130044700_B32","doi-asserted-by":"crossref","unstructured":"Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood\u20082001; 98: 2002\u20137.","DOI":"10.1182\/blood.V98.7.2002"},{"key":"2022061622130044700_B33","doi-asserted-by":"crossref","unstructured":"Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL\/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood\u20082001; 98: 795\u2013804.","DOI":"10.1182\/blood.V98.3.795"},{"key":"2022061622130044700_B34","doi-asserted-by":"crossref","unstructured":"Cruz JC, Alsina M, Craig F, et al. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol\u20082001; 29: 441\u20137.","DOI":"10.1016\/S0301-472X(01)00618-X"},{"key":"2022061622130044700_B35","doi-asserted-by":"crossref","unstructured":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol\u20082003; 121: 749\u201357.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"2022061622130044700_B36","doi-asserted-by":"crossref","unstructured":"Nadav L, Katz BZ, Baron S, et al. Diverse niches within multiple myeloma bone marrow samples affect plasma cell enumeration. Br J Haematol\u20082006; 133: 530\u20132.","DOI":"10.1111\/j.1365-2141.2006.06068.x"},{"key":"2022061622130044700_B37","doi-asserted-by":"crossref","unstructured":"Bartos JD, Stoler DL, Matsui S, et al. Genomic heterogeneity and instability in colorectal cancer: spectral karyotyping, glutathione transferase-Ml, and ras. Mutat Res\u20082004; 568: 283\u201392.","DOI":"10.1016\/j.mrfmmm.2004.06.052"},{"key":"2022061622130044700_B38","doi-asserted-by":"crossref","unstructured":"Anderson GR, Stoler DL, Brenner BM. Cancer: the evolved consequence of a destabilized genome. Bioessays\u20082001; 23: 1037\u201346.","DOI":"10.1002\/bies.1149"},{"key":"2022061622130044700_B39","doi-asserted-by":"crossref","unstructured":"Macaluso M, Paggi MG, Giordano A. Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene\u20082003; 22: 6472\u20138.","DOI":"10.1038\/sj.onc.1206955"},{"key":"2022061622130044700_B40","doi-asserted-by":"crossref","unstructured":"Fan CY. Epigenetic alterations in head and neck cancer: prevalence, clinical significance, and implications. Curr Oncol Rep\u20082004; 6: 152\u201361.","DOI":"10.1007\/s11912-004-0027-0"},{"key":"2022061622130044700_B41","doi-asserted-by":"crossref","unstructured":"Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol\u20082003; 4: 415\u201322.","DOI":"10.1016\/S1470-2045(03)01139-2"},{"key":"2022061622130044700_B42","doi-asserted-by":"crossref","unstructured":"Guikema JE, Hovenga S, Vellenga E, Bos NA. Heterogeneity in the multiple myeloma tumor clone. Leuk Lymphoma\u20082004; 45: 857\u201371.","DOI":"10.1080\/10428190310001593201"},{"key":"2022061622130044700_B43","doi-asserted-by":"crossref","unstructured":"Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol\u20082003; 4: 557\u201364.","DOI":"10.1016\/S1470-2045(03)01195-1"},{"key":"2022061622130044700_B44","doi-asserted-by":"crossref","unstructured":"Peng B, Hodge DR, Thomas SB, et al. Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6\/1 cells. J Biol Chem\u20082005; 280: 4182\u20137.","DOI":"10.1074\/jbc.M412566200"},{"key":"2022061622130044700_B45","doi-asserted-by":"crossref","unstructured":"Schlaepfer DD, Mitra SK, Ilic D. Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta\u20082004; 1692: 77\u2013102.","DOI":"10.1016\/j.bbamcr.2004.04.008"},{"key":"2022061622130044700_B46","doi-asserted-by":"crossref","unstructured":"Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood\u20082004; 103: 2332\u20136.","DOI":"10.1182\/blood-2003-09-3064"},{"key":"2022061622130044700_B47","doi-asserted-by":"crossref","unstructured":"Drewinko B, Alexanian R, Boyer H, Barlogie B, Rubinow SI. The growth fraction of human myeloma cells. Blood\u20081981; 57: 333\u20138.","DOI":"10.1182\/blood.V57.2.333.bloodjournal572333"},{"key":"2022061622130044700_B48","doi-asserted-by":"crossref","unstructured":"Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood\u20082000; 96: 2528\u201336.","DOI":"10.1182\/blood.V96.7.2528.h8002528_2528_2536"},{"key":"2022061622130044700_B49","doi-asserted-by":"crossref","unstructured":"Calvani N, Cafforio P, Silvestris F, Dammacco F. Functional osteoclast-like transformation of cultured human myeloma cell lines. Br J Haematol\u20082005; 130: 926\u201338.","DOI":"10.1111\/j.1365-2141.2005.05710.x"},{"key":"2022061622130044700_B50","doi-asserted-by":"crossref","unstructured":"Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res\u20082005; 11: 7599\u2013606.","DOI":"10.1158\/1078-0432.CCR-05-0523"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/17\/8608\/2552731\/8608.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/17\/8608\/2552731\/8608.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:25:54Z","timestamp":1655425554000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/17\/8608\/526055\/The-Generation-and-Regulation-of-Functional"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,1]]},"references-count":50,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2006,9,1]]},"published-print":{"date-parts":[[2006,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-1301","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,1]]}}}